Eua for Regen-Cov Now Includes COVID-19 Postexposure Prophylaxis.
Am J Nurs
; 121(11): 22, 2021 Nov 01.
Article
in English
| MEDLINE | ID: covidwho-1475853
ABSTRACT
The emergency use authorization for REGEN-COV (a combination of two monoclonal antibodies, casirivimab and imdevimab) has been revised to include postexposure prophylaxis of COVID-19 in adults and children 12 years of age and older who, if they become COVID-19 positive, are at high risk for severe disease.Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Drug Approval
/
Post-Exposure Prophylaxis
/
Antibodies, Monoclonal, Humanized
/
COVID-19
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Adolescent
/
Adult
/
Aged
/
Child
/
Humans
/
Middle aged
/
Young adult
Country/Region as subject:
North America
Language:
English
Journal:
Am J Nurs
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS